Skip to main content
Figure 2 | BMC Pharmacology and Toxicology

Figure 2

From: CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients

Figure 2

Effect of CNX-011-67 on OGTT glucose and insulin levels in n-STZ rats. On day 1 (A) and week 8 (B). Blood samples were collected from the tail vein at the intervals indicated in the graph for estimating insulin and glucose levels. The lower panel represents the OGTT glucose and insulin levels at the end of the study in n-STZ-CNX-011-67 rats on week 8 (C) and week 9 (D) which is one week after agonist withdrawal. In all the experiments, animals were fasted for 16 h and oral glucose administered at 2 g/kg load. On week 8, CNX-011-67 was administered 30 min before oral glucose load. Blood samples were collected from the tail vein at the intervals indicated in the graph for estimating insulin and glucose levels. Open triangle: n-STZ; Closed circle: Sham control; Open square: n-STZ-CNX-011-67. Data in all panels are mean ± SEM (n = 8/group). Statistical comparison between control and treatment group was conducted by one-way ANOVA followed by Dunnett’s post test correction. (*P < 0.05, ** P < 0.01 and *** P < 0.001).

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us